A Phase 3 interventional study of Valbenazine and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Terminated at 3 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 16th largest by enrollment, is one of 2 that started in 2023, is one of 6 in phase 3, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in Bulgaria, Romania, United Kingdom
Ages 18–55
Neurocrine Biosciences · Sites in United States, Puerto Rico, Serbia
Ages 18–65
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Bulgaria, Hungary and 2 more countries
Ages 18–65
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico and 2 more countries
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2023.
This study's enrollment of 8 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Schizophrenia by Neurocrine Biosciences that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963034Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-10 |
| NCT07105098Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-11 |
| NCT07288333Neurocrine BiosciencesEvaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valbenazine once daily
Drug: Valbenazine
Placebo once daily
Drug: Placebo
Oral treatment
Also known as: NBI-98854
Placebo matching valbenazine
Change in Positive and Negative Syndrome Scale (PANSS) Total Score from Baseline to Week 10
Time frame: Baseline, Week 10
Change in Clinical Global Impression of Severity (CGI-S) Score from Baseline to Week 10
Time frame: Baseline, Week 10
Change in Personal and Social Performance (PSP) Score from Baseline to Week 10
Time frame: Baseline, Week 10
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Nov 2023, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine